Business process management firm Visionet expects 50 per cent year-on-year growth in 2021 and 2022 on account of higher demand for digitisation across several verticals, mainly in banking, finance and insurance segments. The company also plans to hire 1,500 people this year.
"In 2020, we have grown by almost 60 per cent overall. In 2021, we are expecting over a 50 per cent plus growth rate and we are also forecasting a very strong growth rate of 50 per cent in 2022. "This is purely an organic growth rate where we are expanding our existing services and offlines in the market," Visionet India managing director and country head Alok Bansal told PTI.
A lot of banking and financial service institutions have expedited their digital journey, he added. According to Bansal, the plans of digitisation of business organisations, which could have taken 1-3 years are now being implemented at the earliest due to the COVID pandemic experience.
"We have secured several orders. Even the existing clients are expanding their volumes, expanding their digital transformation initiatives combined with the new business as well as the existing business. We are looking at almost 1,500 employees overall this year, out of which we have already made an offer to about 500 and 300 people have joined," Bansal said. The new hiring is taking place at the company's facilities in Bengaluru, Coimbatore and Mumbai.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.